"Multiple myeloma is a cancer type that has a great ripple effect depending on new drugs provided in a certain environment. Reimbursement of multiple myeloma treatment requires discussion following a thorough evaluation of the impact of the treatment depending on the treatment environment."

Multiple myeloma is one of the cancer types with increased treatment options following new drug entries.

There are concerns about extending the relapse period and progression-free survival (PFS) as the number of treatments increases due to relapses.

However, the discussion for reimbursement is hindered by cost issues. Youngil Koh, Professor of the Department of Hemato-Oncology at